Form 4: Corcept CDO Sells Shares After Option Exercise

Corcept Therapeutics' Chief Development Officer, William Guyer, exercised stock options and subsequently sold an equal number of common shares under a pre-arranged 10b5-1 plan.

Summary

• William Guyer, Chief Development Officer of Corcept Therapeutics Inc. (CORT), reported transactions on March 20, 2026.
• Guyer exercised stock options to acquire 11,767 shares of common stock at an exercise price of $21.65 per share.
• Concurrently, Guyer sold 11,767 shares of common stock at a weighted average sale price of $36.01 per share, with actual sale prices ranging from $35.97 to $36.24.
• These transactions were executed pursuant to a Rule 10b5-1 trading plan adopted by Guyer on November 27, 2024.
• Following these transactions, Guyer directly beneficially owns 2,231 shares of common stock and 210,000 stock options.
• The common stock ownership includes 224 shares and 498 shares underlying unvested restricted stock awards granted on December 1, 2025, and March 2, 2026, respectively, which vest on their one-year anniversaries.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive event. While an insider sale can sometimes be a negative signal, the execution under a 10b5-1 plan mitigates concerns, and the profitable exercise of options reflects positively on the company's stock performance relative to the option grant price.

Positives

• The officer exercised options at $21.65 and sold shares at a significantly higher weighted average price of $36.01, indicating a profitable transaction for the insider.
• The transaction was conducted under a pre-arranged 10b5-1 plan, which suggests a systematic approach to managing personal holdings rather than a reaction to immediate company news.

Negatives

• The sale of shares by a Chief Development Officer, even if planned, could be perceived by some investors as a slight negative, though it's a common practice for executives to monetize vested options.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that insider transactions, particularly those executed under Rule 10b5-1 plans, are common occurrences in the public markets. These plans allow insiders to sell a predetermined number of shares at a predetermined time or price, helping them manage personal finances while avoiding accusations of trading on material non-public information. This specific transaction by Corcept's CDO is consistent with typical executive compensation and liquidity management practices.

Stakeholder Impact

• Shareholders: The transaction provides transparency into insider holdings and planned sales, which can inform investment decisions. The profitable sale by an executive might be seen as a positive indicator of past stock performance.
• Employees: No direct impact mentioned, but executive compensation practices are often observed by employees.

Key Dates

Recommendation

This Form 4 filing details a routine, pre-planned insider transaction (exercise of options and subsequent sale of shares) by a Chief Development Officer. Such transactions, especially under a 10b5-1 plan, are generally not considered a strong indicator for future stock performance and do not typically warrant a change in investment recommendation. The profitability of the transaction for the insider is a positive, but it's a personal liquidity event rather than a strategic company move. Therefore, a 'hold' recommendation is appropriate as this filing alone does not present new material information to alter the investment thesis for Corcept Therapeutics.

Keywords

Corcept Therapeutics, CORT, Insider Trading, Form 4, Stock Option Exercise, Share Sale, 10b5-1 Plan, William Guyer, Chief Development Officer